Multiple Sclerosis and Neuroimmunology Clinical Trials

An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis 

Two arms currently enrolling:
Arm 4: RMS
 - delayed start, remain on current treatment for 3 months; inclusion requires one relapse in past year, or one Gd+ or new T2 lesion
Arm 5: PPMS
 - EDSS 3.0-6.5, CSF +ve for OCB or elevated IgG index 

Exclusions: previous treatment with Tysabri, Lemtrada, Aubagio; treatment with Gilenya or Tecfidera within 6 months prior to enrollment
PI: Christopher Lock
Kara Richardson, Clinical Research Manager

A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
Sponsor: Novartis

Analysis of Cytokine Modulation with Tecfidera in Human Immune Cell Subsets Using High Dimensional Flow Cytometry and CYTOF Mass Spectrometry
Eprotocol number 29046
This is an open label longitudinal study analyzing peripheral blood lymphocyte subsets in patients with Relapsing Remitting Multiple Sclerosis (RRMS) that are on Tecfidera.
PI: Lawrence Steinman, MD
Study Active, Enrollment Closed

Blood, CSF and Tissue Repository To Identify Biomarkers in Multiple Sclerosis
Stanford Protocol #16691
Sponsor: Stanford University
PI: May Han, MD
Study Active, Enrollment Open

Multicenter, Randomized, Double-Blind, Parallel-Group Extension to Study AC-058B201 to Investigate the Long-Term Safety, Tolerability, and Efficacy of 10, 20, and 40 mg/day ACT-128800, an Oral S1P1 Receptor Agonist, in Patients with Relapsing-Remitting Multiple Sclerosis
Sponsor: Actelion Pharmaceuticals Ltd
PI: Jeffrey Dunn, MD
Study Active, Enrollment Closed

Blood repository study to identify biomarkers in NMO and MS patients to predict treatment effectiveness
Stanford protocol #326196
PI: Lawrence Steinman, MD
Study active, enrollment closed

Analysis of antibodies and immune responses in demyelinating disease
Stanford protocol #34529
PI: William Robinson, MD, PhD
Study active, enrollment open

A Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif ®) in Patients with Relapsing Multiple Sclerosis
Sponsor: Genentech
PI: Jeffrey Dunn, MD
Study active, enrollment closed

Effects of aquatic therapy in multiple sclerosis patients
Stanford protocol #39711
PI: Christopher Lock, MD
Study active, enrollment open

Clinical Trials Contact

Kara Richardson
Co-Manager, Stanford Neuroscience Clinical Research Group
Clinical Research Coordinator
Neurosurgery and Neurology Departments
Stanford School of Medicine
(650) 736-6171